Nanosonics Limited (NNCSF) Research
Nanosonics Limited, in conjunction with its subsidiaries, functions as an infection prevention enterprise, serving both Australian and international markets. The company's core activities involve the production and supply of the trophon ultrasound probe disinfector, alongside its complementary consumables and accessories. Furthermore, Nanosonics is committed to the research, development, and market introduction of innovative infection control and decontamination products and related technologies. Its product portfolio features the trophon2, a sophisticated device for high-level disinfection of ultrasound probes; trophon EPR, a specialized low-temperature, high-level disinfection solution specifically for intra-cavity ultrasound transducers; and Nanosonics AuditPro, a comprehensive system for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited maintains its corporate headquarters in Macquarie Park, Australia.
Market snapshot
- Symbol
- NNCSF
- Price
- $2.36
- Day change
- 0.00%
- Market cap
- $989.4M
- P/E ratio
- 48.91x
- 52-week range
- 2.01-3.0575
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Next earnings
- in 2 months
Peer companies
Open Nanosonics Limited (NNCSF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.